Update: Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals

• 2024

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

This update from the Pediatric Pandemic Network (PPN) describes the new guidelines from the CDC with additional recommendations from the FDA, AAP, and AAFP. There are detailed answers regarding who should receive the vaccine when available, how to prepare for administration, billing, and other common questions healthcare providers may have about Nirsevimab.

---

Tags

Focus Area: Infectious Disease

Audiences: Emergency Managers; Nurses; Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Central Supply, Hospital; Pediatrics; Respiratory Syncytial Viruses; Vaccines; Immunization Programs; Respiratory Syncytial Virus Vaccines; Health Equity

Institutions: Pediatric Pandemic Network (PPN)

---

More like this

National Assessment Highlights Impact of COVID-19 on Pediatric Capabilities of Emergency Departments – With Implications for Survival 2023 · Pediatric Pandemic Network (PPN) Pediatric Respiratory Virus Surge Response - Fall/Winter 2022-23 2023 · Pediatric Pandemic Network (PPN) Empowering Pediatric Healthcare for Crisis Readiness 2024 · Healthcare Ready, Pediatric Pandemic Network (PPN)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---